Personal paper: New drug treatment for Alzheimer's disease: lessons for healthcare policy
- 7 March 1998
- Vol. 316 (7133) , 762-764
- https://doi.org/10.1136/bmj.316.7133.762
Abstract
Alzheimer's disease is a common and devastating condition, and the launch of a specific treatment naturally attracted intense interest. The new drug, donepezil (Aricept), an anticholinesterase agent, was licensed in the United States in December 1996, with reports that it had produced “highly significant improvements in cognitive and clinical global assessments” in randomised trials lasting 30 weeks and had increased the proportion of “treatment successes” by 245%.1Keywords
This publication has 7 references indexed in Scilit:
- Advertisements for donepezil (Aricept) in the BMJ. Advertisement suggests an unrealistic improvement in mental status.1997
- Advertisements for donepezil (Aricept) in the BMJ. Local committee has declined to approve NHS hospital prescription of donepezil.1997
- Research suppressed for seven years by drug companyBMJ, 1997
- Drug treatments for Alzheimer's diseaseBMJ, 1997
- Policy issues in the private health sector: Examples from long-term care in the U.K.Social Science & Medicine, 1996
- Technology Assessment:Old, New, and Needs-basedInternational Journal of Technology Assessment in Health Care, 1995
- The UK Community Care Act (1990) and the elderlyThe Lancet, 1994